Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Recent studies have shown that members of the inhibitor of apoptosis (IAP) protein family are highly expressed in several classes of cancer.The primary implication of these findings is that the elevated expression of IAPs is not coincidental but actually participates in oncogenesis by helping to allow the malignant cell to avoid apoptotic cell death.This concept, together with the discovery of several IAP-regulatory proteins that use a conserved mode of action, has stimulated a major effort by many research groups to devise IAP-targeting strategies as a means of developing novel antineoplastic drugs.In this Review, we consider the evidence both for and against the IAPs being valid therapeutic targets, and we describe the types of strategies being used to neutralize their functions. IAPs: structure and functionInhibitor of apoptosis (iap) genes were first described in insect viruses through a genetic screen to identify compensatory replacements for the loss of the baculoviral antiapoptotic p35 protein, which functions to block baculovirus-induced apoptosis during infection (1-3).Since the initial identification in baculoviruses, iap homologs have been identified across phyla from Caenorhabditis elegans and yeast to insects and mammals.As many as 8 human iap gene products have been identified (reviewed in ref. 4), XIAP (hILP/ MIHA/BIRC4), hILP-2 (TS-IAP), cellular IAP1 (c-IAP1/HIAP2/ MIHB/BIRC2), cellular IAP2 (c-IAP2/HIAP1/MIHC/BIRC3), melanoma-associated IAP (ML-IAP/Livin/KIAP1/BIRC7), neuronal apoptosis-inhibitory protein (NAIP/BIRC1), survivin (TIAP1/ BIRC5), and Apollon (BRUCE/BIRC6) (Figure 1A).These IAP proteins have been shown to play, for the most part, nonredundant cellular roles that range from apoptotic inhibition to the formation of the mitotic spindle during cytokinesis.For this reason, the term "IAP" is somewhat misleading, and these factors are often referred to as BIR-containing proteins, or BIRPs (5), a term derived from the presence of what has become the defining motif of this family, an approximately 65-residue domain rich in histidines and cysteines known as the baculovirus iap repeat (BIR).BIRPs contain 1-3 imperfectly repeated BIRs (Figure 1).Most of the IAP family members also harbor a RING domain at the carboxy terminus.The RING functions as an E3 ubiquitin ligase, which is preceded by ubiquitinactivating enzymes (E1) and ubiquitin-conjugating enzymes (E2) in the cascade of protein ubiquitination (6-9).E3 ubiquitin ligases provide specificity for the transfer of ubiquitin moieties onto the target protein.Therefore, IAP-mediated protein ubiquitination has a pivotal role in the regulation of apoptosis, allowing the IAP to control stability of itself and other proteins (10). IAPs in cancerMany studies have revealed a circumstantial association of IAPs and neoplasia (25).For example, XIAP levels are elevated in many Nonstandard abbreviations used: ASO, antisense oligonucleotide; BIR, baculovirus iap repeat; BIRP, BIR-containing protein; c-IAP, cellular IAP; Hid, head involution defective; IAP, inhibitor of apoptosis; IBM, IAP-binding motif; ML-IAP, melanoma-associated IAP; Rpr, reaper; Smac/DIABLO, second mitochondria-derived activator of caspase/direct IAP-binding protein with low pI; TRAIL, TNF-related apoptosis-inducing ligand.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Luo, X., Budihardjo, I., Zou, H., Slaughter, C., & Wang, X. (1998) · Cell · doi:10.1016/s0092-8674(00)81589-5 · Cited by 3,626
Du, C., Fang, M., Li, Y., Li, L., & Wang, X. (2000) · Cell · doi:10.1016/s0092-8674(00)00008-8 · Cited by 3,513
IAP proteins: blocking the road to death's door
Salvesen, G. S., & Duckett, C. S. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm830 · Cited by 1,756
Chu, Z.-L., McKinsey, T. A., Liu, L., Gentry, J. J., Malim, M. H., & Ballard, D. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10057 · Cited by 872
Cited by
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach
Zender, L., Spector, M. S., Xue, W., Flemming, P., Cordon-Cardo, C., Silke, J., Fan, S.-T., Luk, J. M., Wigler, M., Hannon, G. J., et al. (2006) · Cell · doi:10.1016/j.cell.2006.05.030 · Cited by 1,065
“Similarly, IAP expression has been associated with various cancer phenotypes (Wright and Duckett, 2005), but no IAP has been decisively linked to tumorigenesis in vivo.”
BackgroundInfluentialUnderstanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics
Jan, R., & Chaudhry, G.-E.-S. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.024 · Cited by 899
Molecular Mechanisms of Apoptosis and Roles in Cancer Development and Treatment
Goldar, S., Khaniani, M. S., Derakhshan, S. M., & Baradaran, B. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.6.2129 · Cited by 606
Targeting the ubiquitin system in cancer therapy
Hoeller, D., & Dikic, I. (2009) · Nature · doi:10.1038/nature07960 · Cited by 599
Staudt, L. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000109 · Cited by 485
Metadata
- Authors
- Wright, C. W.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-10-01
- Volume
- 115
- Issue
- 10
- Pages
- 2673-2678
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2140433977
- Cited by
- 114
- References
- 4
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. https://app.cochat.ai/papers/10.1172/jci26251
- The paper
- Wright, C. W. (2005). Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. Journal of Clinical Investigation. https://doi.org/10.1172/jci26251
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.